OX338

OX338 is an investigational **oral tablet formulation of ketorolac** being developed by **Orexo** for the **short-term treatment of moderate to moderately severe acute pain requiring analgesia at the opioid level**. It is a **small-molecule nonsteroidal anti-inflammatory drug formulation** designed for **rapid absorption and onset of analgesic effect**. Its pharmacology is expected to reflect ketorolac's inhibition of the **cyclooxygenase prostaglandin pathway**, providing potent analgesia without the abuse liability associated with opioids. Based on the provided development context, OX338 showed improved bioavailability and tolerability versus reference ketorolac products in a 2020 pharmacokinetic study, with one formulation demonstrating faster absorption, after which further formulation optimization was planned.

Other names

ketorolac tablet formulation